FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149013235> ?p ?o ?g. }

• W2149013235 endingPage "116" @default.
• W2149013235 startingPage "106" @default.
• W2149013235 abstract "The aim of the current study was to investigate the therapeutic effect of 227Th-radioimmunotherapy on intraperitoneally growing human bioluminescent HER2 positive ovarian cancer cells. Methods: In vitro toxicity of 227Th-trastuzumab in bioluminescent SKOV3-luc-D3 ovarian cancer cells was assessed in a growth assay. The biodistribution of intraperitoneally administrated 227Th-trastuzumab in athymic nude mice without tumor cells was determined. For in vivo therapy, seventy female athymic nude mice were intraperitoneally inoculated with tumor cells 17 days prior to injection of single 227Th-trastuzumab doses of 1000 kBq/kg, 600 kBq/kg or 400 kBq/kg, or three injections with 400 kBq/kg 227Th-trastuzumab separated by 4 weeks. Two control groups were given either 20 µg unlabeled trastuzumab or 0.9 % NaCl. In vivo bioluminescence imaging was performed weekly before and after onset of therapy. Tumor growth, survival and toxicity were compared. Results: There was a statistically significant therapeutic effect of the 227Th-trastuzumab treatment both with respect to survival and tumor growth. The maximum tolerated dosage was 600 kBq/kg 227Th-trastuzumab. In the in vitro study, two hours incubation with 20 kBq/ml of 227Th-trastuzumab, followed by washing, and subsequent culture of the cells resulted in an average absorbed radiation dose of 6 Gy after 11 days and complete growth inhibition. Conclusion: Targeted alpha therapy with 227Th-trastuzumab of human SKOV3-luc-D3 cells growing intraperitoneally in nude mice was clearly superior to unlabeled trastuzumab therapy. The results warrant further studies of 227Thradioimmunotherapy used as adjuvant treatment and for metastatic cancer. Keywords: Radioimmunotherapy, targeted alpha therapy, Thorium-227, trastuzumab, bioluminescence, alpha particle, ovarian cancer." @default.
• W2149013235 created "2016-06-24" @default.
• W2149013235 creator A5035210535 @default.
• W2149013235 creator A5035939033 @default.
• W2149013235 creator A5055489849 @default.
• W2149013235 creator A5064961032 @default.
• W2149013235 creator A5079375927 @default.
• W2149013235 creator A5081109337 @default.
• W2149013235 date "2013-06-01" @default.
• W2149013235 modified "2023-10-17" @default.
• W2149013235 title "Targeted Alpha Therapy with 227Th-trastuzumab of Intraperitoneal Ovarian Cancer in Nude Mice" @default.
• W2149013235 cites W1639752340 @default.
• W2149013235 cites W1981989535 @default.
• W2149013235 cites W1993470607 @default.
• W2149013235 cites W1997836196 @default.
• W2149013235 cites W200200375 @default.
• W2149013235 cites W2035018304 @default.
• W2149013235 cites W2042548235 @default.
• W2149013235 cites W2046793599 @default.
• W2149013235 cites W2071889409 @default.
• W2149013235 cites W2075539380 @default.
• W2149013235 cites W2105074988 @default.
• W2149013235 cites W2125544080 @default.
• W2149013235 cites W2137869150 @default.
• W2149013235 cites W2145312678 @default.
• W2149013235 cites W2164082174 @default.
• W2149013235 cites W2168215168 @default.
• W2149013235 doi "https://doi.org/10.2174/18744710113069990018" @default.
• W2149013235 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23551111" @default.
• W2149013235 hasPublicationYear "2013" @default.
• W2149013235 type Work @default.
• W2149013235 sameAs 2149013235 @default.
• W2149013235 citedByCount "31" @default.
• W2149013235 countsByYear W21490132352013 @default.
• W2149013235 countsByYear W21490132352014 @default.
• W2149013235 countsByYear W21490132352015 @default.
• W2149013235 countsByYear W21490132352016 @default.
• W2149013235 countsByYear W21490132352017 @default.
• W2149013235 countsByYear W21490132352018 @default.
• W2149013235 countsByYear W21490132352020 @default.
• W2149013235 countsByYear W21490132352021 @default.
• W2149013235 countsByYear W21490132352022 @default.
• W2149013235 countsByYear W21490132352023 @default.
• W2149013235 crossrefType "journal-article" @default.
• W2149013235 hasAuthorship W2149013235A5035210535 @default.
• W2149013235 hasAuthorship W2149013235A5035939033 @default.
• W2149013235 hasAuthorship W2149013235A5055489849 @default.
• W2149013235 hasAuthorship W2149013235A5064961032 @default.
• W2149013235 hasAuthorship W2149013235A5079375927 @default.
• W2149013235 hasAuthorship W2149013235A5081109337 @default.
• W2149013235 hasConcept C121608353 @default.
• W2149013235 hasConcept C126322002 @default.
• W2149013235 hasConcept C150903083 @default.
• W2149013235 hasConcept C159654299 @default.
• W2149013235 hasConcept C185592680 @default.
• W2149013235 hasConcept C202751555 @default.
• W2149013235 hasConcept C203014093 @default.
• W2149013235 hasConcept C207001950 @default.
• W2149013235 hasConcept C2776146153 @default.
• W2149013235 hasConcept C2777807558 @default.
• W2149013235 hasConcept C2777863537 @default.
• W2149013235 hasConcept C2779707156 @default.
• W2149013235 hasConcept C2779786085 @default.
• W2149013235 hasConcept C2780427987 @default.
• W2149013235 hasConcept C502942594 @default.
• W2149013235 hasConcept C530470458 @default.
• W2149013235 hasConcept C542903549 @default.
• W2149013235 hasConcept C55493867 @default.
• W2149013235 hasConcept C71924100 @default.
• W2149013235 hasConcept C86803240 @default.
• W2149013235 hasConcept C98274493 @default.
• W2149013235 hasConceptScore W2149013235C121608353 @default.
• W2149013235 hasConceptScore W2149013235C126322002 @default.
• W2149013235 hasConceptScore W2149013235C150903083 @default.
• W2149013235 hasConceptScore W2149013235C159654299 @default.
• W2149013235 hasConceptScore W2149013235C185592680 @default.
• W2149013235 hasConceptScore W2149013235C202751555 @default.
• W2149013235 hasConceptScore W2149013235C203014093 @default.
• W2149013235 hasConceptScore W2149013235C207001950 @default.
• W2149013235 hasConceptScore W2149013235C2776146153 @default.
• W2149013235 hasConceptScore W2149013235C2777807558 @default.
• W2149013235 hasConceptScore W2149013235C2777863537 @default.
• W2149013235 hasConceptScore W2149013235C2779707156 @default.
• W2149013235 hasConceptScore W2149013235C2779786085 @default.
• W2149013235 hasConceptScore W2149013235C2780427987 @default.
• W2149013235 hasConceptScore W2149013235C502942594 @default.
• W2149013235 hasConceptScore W2149013235C530470458 @default.
• W2149013235 hasConceptScore W2149013235C542903549 @default.
• W2149013235 hasConceptScore W2149013235C55493867 @default.
• W2149013235 hasConceptScore W2149013235C71924100 @default.
• W2149013235 hasConceptScore W2149013235C86803240 @default.
• W2149013235 hasConceptScore W2149013235C98274493 @default.
• W2149013235 hasIssue "2" @default.
• W2149013235 hasLocation W21490132351 @default.
• W2149013235 hasLocation W21490132352 @default.
• W2149013235 hasOpenAccess W2149013235 @default.
• W2149013235 hasPrimaryLocation W21490132351 @default.
• W2149013235 hasRelatedWork W1970501874 @default.

• next